Overview

This trial is active, not recruiting.

Condition abdominoplasty
Treatments ablation and skin resurfacing, ematrixco2
Phase phase 2/phase 3
Sponsor Syneron Medical
Start date November 2009
End date April 2010
Trial size 5 participants
Trial identifier NCT01026662, eMatrixCO2 Preab

Summary

This study will:

Evaluate the in vivo effects of treatment with eMatrixCO2 and to determine the dynamics of their development over time following treatment.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Arm
Subjects scheduled for abdominoplasty surgery
ablation and skin resurfacing
Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
ematrixco2

Primary Outcomes

Measure
Histological and molecular assessment of tissue taken following treatment with different parameters and at various time points
time frame: Immediate, 1, 3, 10, 30 days
Record number and type of any AE during the study
time frame: Throughout study

Eligibility Criteria

Male or female participants from 20 years up to 60 years old.

Inclusion Criteria: - Informed consent agreement signed by the subject. - Healthy males or females older than 21 to 60 years of age. - Fitzpatrick skin type I-V (Although the systems are cleared for all skin types I-VI, it is recommended to use the Matrix applicators on skin types I - V). - Willingness to follow the treatment and follow-up schedule and the post-treatment care. - For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence). Exclusion Criteria: - Pregnant and/or breastfeeding. - Having a history of diseases stimulated by heat, such as recurrent Herpes - Simplex in the treated area, unless treatment is conducted following a prophylactic regimen. - Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session. - Use of retinoids, antioxidants or therapeutic skin nourishing supplements at medicinal concentration within 2 months of treatment or during the study and oral retinoids within 6 months of the study. - Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study. - Having received collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study. - Having received Botox in the treated area within 6 months of treatment or during the study. - Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study. - History of keloid scarring or of abnormal wound healing. - Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course. - History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. - History of epidermal or dermal disorders (particularly if involving collagen or microvascularity). - History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. - Suffering from hormonal imbalance, as per the Investigator's discretion. - Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion). - Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions. - Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders. Vascular lesion, tattoo or permanent make-up in the treated area. - Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. - Participation in a study of another device or drug within three month prior to enrollment or during the study. - As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Additional Information

Official title In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue
Trial information was received from ClinicalTrials.gov and was last updated in April 2010.
Information provided to ClinicalTrials.gov by Syneron Medical.